EICHORCondition: Arthritis, Psoriatic · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Arizona Arthritis and Rheumatology Research PLLC | Phoenix, Arizona, United States | — |
| Arizona Arthritis and Rheumatology Research PLLC 1 | Phoenix, Arizona, United States | — |
| Unity Health-White County Medical Center | Searcy, Arkansas, United States | — |
| HARAC Research Corp | Avon Park, Florida, United States | — |
| Bay Pines VA Healthcare System | Bay Pines, Florida, United States | — |
| Omega Research Consultants | DeBary, Florida, United States | — |
| South Coast Research Center | Miami, Florida, United States | — |
| Advanced Clinical Research of Orlando | Ocoee, Florida, United States | — |
| Millennium Research | Ormond Beach, Florida, United States | — |
| Atlanta Research Center for Rheumatology | Marietta, Georgia, United States | — |
| Great Lakes Center of Rheumatology | Lansing, Michigan, United States | — |
| Clinvest | Springfield, Missouri, United States | — |
+ 70 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05071664